Budúce P/E spoločnosti PureTech Health Plc
Aká je hodnota metriky Budúce P/E spoločnosti PureTech Health Plc?
Hodnota metriky Budúce P/E spoločnosti PureTech Health Plc je -505.47
Aká je definícia metriky Budúce P/E?
Budúci pomer P/E (Forward price to earnings ratio) vyjadruje pomer súčasnej ceny a odhadovaného zisku na akciu za ďalších 12 mesiacov.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Budúce P/E spoločností v sektore Health Care sektor na LSE v porovnaní so spoločnosťou PureTech Health Plc
Čomu sa venuje spoločnosť PureTech Health Plc?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Firmy s metrikou budúce p/e podobnou spoločnosti PureTech Health Plc
- Hodnota metriky Budúce P/E spoločnosti Regis je -2,236.00
- Hodnota metriky Budúce P/E spoločnosti Freshpet Inc je -1,232.16
- Hodnota metriky Budúce P/E spoločnosti Hutchison China MediTech je -995.34
- Hodnota metriky Budúce P/E spoločnosti LXP Industrial Trust je -987.00
- Hodnota metriky Budúce P/E spoločnosti Cronos je -807.00
- Hodnota metriky Budúce P/E spoločnosti Sterling Plc je -752.00
- Hodnota metriky Budúce P/E spoločnosti PureTech Health Plc je -505.47
- Hodnota metriky Budúce P/E spoločnosti Kite Realty Trust je -475.31
- Hodnota metriky Budúce P/E spoločnosti Applied Optoelectronics Inc je -446.00
- Hodnota metriky Budúce P/E spoločnosti Cedar Realty Trust Inc je -414.29
- Hodnota metriky Budúce P/E spoločnosti Sunrun Inc je -401.12
- Hodnota metriky Budúce P/E spoločnosti ITM Power Plc je -325.71
- Hodnota metriky Budúce P/E spoločnosti Trilogiq SA je -324.00